<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Mazdutide: what changed | Grey Peptides</title>
    <link>https://greypeptides.com/changes/#e-mazdutide</link>
    <atom:link href="https://greypeptides.com/changes/mazdutide.xml" rel="self" type="application/rss+xml" />
    <description>News, regulatory alerts, corrections and new guides about Mazdutide on Grey Peptides, newest first.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 31 Mar 2026 12:00:00 +0000</lastBuildDate>
    <ttl>1440</ttl>
    <item>
      <title>Regulatory alert: US FDA: FDA warned two online sellers, in California and Arizona, that retatrutide, tirzepatide, semaglutide, cagrilintide and mazdutide, sold under code names such as 'GLP-1-R peptide' and 'GLP1-T', are unapproved new drugs. Posted April 7.</title>
      <link>https://greypeptides.com/regulatory/alerts/#fda-wl-two-online-sellers-march</link>
      <guid isPermaLink="false">greypeptides-changes-mazdutide-alert-fda-wl-two-online-sellers-march</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>The code names did not hide the drugs, and 'laboratory research purposes only' labels did not change FDA's finding. Bacteriostatic water sold alongside was again part of the evidence.</description>
    </item>
  </channel>
</rss>
